A Controlled Trial of Erenumab for Episodic Migraine | NEJM
Aimovig® (erenumab-aooe) for the Preventive Treatment of Migraine in Adults
Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice | SpringerLink
Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials | Scientific Reports
Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine | Novartis
Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention | Novartis
JCM | Free Full-Text | Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
Methodologies and outcomes of clinical trials of erenumab in episodic... | Download Scientific Diagram
Early onset of efficacy with erenumab in patients with episodic and chronic migraine | The Journal of Headache and Pain | Full Text
Migraine prevention with erenumab | TCRM
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study | Journal of Neurology, Neurosurgery & Psychiatry
Long-term Efficacy and Safety of Erenumab | Neurology
One-year sustained efficacy of erenumab in episodic migraine | Neurology
Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study - touchNEUROLOGY
PDF) A Controlled Trial of Erenumab for Episodic Migraine
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study - The Lancet
A Controlled Trial of Erenumab for Episodic Migraine | NEJM
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study - The Lancet
Frontiers | Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal | The Journal of Headache and Pain | Full Text
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study - Shuu-Jiun Wang, Artemio A Roxas, Bibiana Saravia,
Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies | Novartis
